AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director

by Barry101 | Feb 26, 2025 | Press Release

OCALA, Fla., Feb. 26, 2025 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Company’s Board of Directors (the “Board”) has, by unanimous vote, appointed David Chemerow as an...

AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer

by Barry101 | Feb 25, 2025 | Press Release

Several subjects who received the highest dose in Phase 1 will also be included in Phase 2OCALA, Fla., Feb. 25, 2025 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the first new subject has been...

AIM ImmunoTech Releases Virtual Investor “What This Means Segment”

by Barry101 | Feb 11, 2025 | Press Release

Tom Equels, CEO of AIM ImmunoTech and Professor Casper H.J. van Eijck, MD, PhD, Pancreato-biliary Surgeon at Erasmus MC, discuss the Phase 1b/2 clinical trial involving AIM’s Ampligen® (rintatolimod) and AstraZeneca’s anti-PD-L1 immune checkpoint...

AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024

by Barry101 | Feb 11, 2025 | Press Release

OCALA, Fla., Feb. 11, 2025 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual...

AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM’s Ampligen® and AstraZeneca’s FluMist® to address the recent avian influenza outbreaks

by Barry101 | Feb 7, 2025 | Press Release

Planned Investigational New Drug application to expand on previous clinical work at the University of Alabama-Birmingham in which administration of Ampligen as an intranasal adjuvant increased immune response, including cross-protection via avian influenza antibody...

Erasmus Medical Center Safety Committee Grants Approval to Proceed with Phase 2 Study of Ampligen® and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer

by Barry101 | Feb 5, 2025 | Press Release

Safety Committee approval based on positive Phase 1 safety data demonstrating the combination therapy to be generally well-tolerated with no severe treatment-related adverse events or dose-limiting toxicities Enrollment for Phase 2 expected to commence imminently...